This was taken from one of the past slide show presentations. I'm just guessing, but I think they are a year behind these statements because I don't recall any update on the Australian trial. I'm all for the social media campaign, but let's get some solid updates on these endeavors.


In January 2018, a development agreement was entered into with ECM world-leader Cook Biotech, Inc. to provide support for the development and manufacture of ECMH. As part of this arrangement, Cook Biotech became a shareholder of Regentys. Currently, the company is working to finalize production batches of ECMH for use in clinical trials expected to begin mid-2019 at a site in Australia.

Regentys plans to complete pilot and pivotal studies in late 2019 and 2020 and to apply for approval to market ECMH in Q4 2020. Management expects to expand the clinical utility of Regentys ECMH™ to obtain approval in additional therapeutic indications including Crohn’s and other gastrointestinal disorders thereafter.